GAMMA Investing LLC Buys 22,721 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

GAMMA Investing LLC increased its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 3,595.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 23,353 shares of the life sciences company's stock after purchasing an additional 22,721 shares during the quarter. GAMMA Investing LLC's holdings in Integra LifeSciences were worth $5,140,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Arrowstreet Capital Limited Partnership boosted its stake in Integra LifeSciences by 7.1% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company's stock valued at $312,000 after purchasing an additional 913 shares during the period. Quadrant Capital Group LLC grew its holdings in shares of Integra LifeSciences by 5,960.9% in the 4th quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock worth $32,000 after acquiring an additional 1,371 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Integra LifeSciences by 3.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,466 shares of the life sciences company's stock worth $872,000 after purchasing an additional 1,437 shares in the last quarter. Sterling Capital Management LLC raised its holdings in shares of Integra LifeSciences by 821.7% during the fourth quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock valued at $49,000 after acquiring an additional 1,931 shares during the period. Finally, Covestor Ltd raised its stake in Integra LifeSciences by 61.8% during the 4th quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock valued at $123,000 after purchasing an additional 2,071 shares during the period. 84.78% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. JPMorgan Chase & Co. lowered their price target on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. JMP Securities dropped their target price on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a report on Friday, May 9th. Truist Financial cut their price target on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a report on Friday, April 11th. Wells Fargo & Company reduced their target price on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Finally, Argus upgraded shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a research note on Monday, March 31st. Four research analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $18.63.

Integra LifeSciences Price Performance

Shares of NASDAQ:IART traded down $0.14 during trading on Thursday, reaching $12.69. The stock had a trading volume of 1,696,766 shares, compared to its average volume of 1,046,665. The business's 50-day moving average price is $14.62 and its 200 day moving average price is $20.32. Integra LifeSciences Holdings Co. has a 52 week low of $11.60 and a 52 week high of $32.66. The stock has a market capitalization of $986.17 million, a PE ratio of -140.98, a P/E/G ratio of 0.73 and a beta of 1.16. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The life sciences company reported $0.41 earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.02). Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $382.65 million during the quarter, compared to analyst estimates of $381.17 million. During the same quarter in the previous year, the business posted $0.55 EPS. The company's revenue was up 3.7% compared to the same quarter last year. As a group, equities analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.